---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-112930"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:02:49.341235+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics receives Nasdaq delisting notice; plans to appeal

## Summary
- Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.
- Company intends to request hearing by Oct 8, 2024; hearing automatically stays suspension.
- Expects to regain compliance upon closing pending merger with Peak Bio, Inc.
- No assurance of success; shares at risk of suspension if appeal fails.

## SEC filing metadata
- accession: 0000950170-24-112930
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/0000950170-24-112930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/aktx-20241001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-112930
- JSON: https://secwatch.observer/filing/0000950170-24-112930.json
- Plain text: https://secwatch.observer/filing/0000950170-24-112930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.